Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Muscle Protein Synthesis After Whole Egg vs. Egg White Consumption

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03117127
Recruitment Status : Completed
First Posted : April 17, 2017
Last Update Posted : May 1, 2018
Sponsor:
Information provided by (Responsible Party):
Nicholas Burd, University of Illinois at Urbana-Champaign

Brief Summary:
In crossover trials, ten (N=10) young men (18-35 y) will receive stable isotope tracer infusions and perform a single bout of resistance exercise. Immediately after resistance exercise, participants will ingest stable isotope labeled whole eggs (18 g protein, 17 g fat) or egg whites (18 g protein, 0 g fat) cooked in scrambled form. Repeated blood and muscle biopsies will be collected to determine whole body amino acid kinetics, muscle amino acid transporters, anabolic signaling and myofibrillar protein synthesis rates during the trials.

Condition or disease Intervention/treatment Phase
Hypertrophy Behavioral: Resistance Exercise Other: Whole Eggs Other: Egg Whites Not Applicable

Detailed Description:

On both infusion trials, participants will report to the laboratory at 0700 h after an overnight fast. Upon arrival to the lab, a baseline breath sample will be collected for determination of 13CO2 enrichment by isotope ratio mass spectrometry. A Teflon catheter will be inserted into an antecubital vein for baseline blood sample collection (t=-210 min) and then participants will receive priming doses of NaH13CO2 (2.35 µmol·kg-1), L-[1-13C]leucine (7.6 µmol·kg-1), and L-[ring-2H5]phenylalanine (2.0 µmol·kg-1). Subsequently, a continuous intravenous infusion of L-[1-13C]leucine (0.10 µmol·kg-1·min-1) and L-[ring-2H5]phenylalanine (0.05 µmol·kg-1·min-1) will be initiated (t=-210 min) and maintained over the infusion trials. A second Teflon catheter willinserted into a heated dorsal hand vein for repeated arterialized blood sampling and remained patent by a 0.9% saline drip. Breath samples and arterialized blood samples and will be collected every 30 or 60 min during the postabsorptive- and postprandial states. In the post-absorptive state of infusion trial 1, muscle biopsies will be collected at t=-150 and -30 min of infusion to determine basal-state myofibrillar protein synthesis rates, relative skeletal muscle amino acid transporter content, and anabolic-related signaling. In the subsequent cross-over trial only 1 muscle biopsy will be collected at t=-30 for Western blot analysis and postabsorptive myofibrillar protein-bound tracer enrichment. After collection of the resting muscle biopsy at t=-30 for both trials, the participants will perform resistance exercise that consists of 4 sets of 10 repetitions at 80% of 10-RM for both leg press and leg extension exercise.

Immediately after completion of the exercise bout, participants will consume 3 whole eggs or an equivalent amount of protein from egg whites (t=0 min). Completion of the meal will mark the start of the postprandial phase (t=0 min) and additional muscle biopsies will be collected at t=120 and 300 min.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: The Consumption of Whole Eggs Versus Egg Whites to Stimulate Postprandial Muscle Protein Synthesis
Actual Study Start Date : July 2015
Actual Primary Completion Date : February 2017
Actual Study Completion Date : May 2017

Arm Intervention/treatment
Active Comparator: Whole eggs
After resistance exercise, participants will ingest whole eggs (18 g protein, 17 g fat) cooked in scrambled form.
Behavioral: Resistance Exercise
Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites

Other: Whole Eggs
Participants will ingestion whole eggs immediately after resistance exercise

Experimental: Egg Whites
After resistance exercise, participants will ingest egg whites (18 g protein, 0 g fat) cooked in scrambled form.
Behavioral: Resistance Exercise
Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites

Other: Egg Whites
Participants will ingestion whole eggs immediately after resistance exercise




Primary Outcome Measures :
  1. Fractional synthetic rate of myofibrillar proteins to whole egg and egg white ingestion [ Time Frame: Postabsorptive for 3 hours, Postprandial for 5 hours ]
    Myofibrillar protein synthesis rates will be assessed during the postabsorptive period for 3 hr and during the 5 hr after the ingestion of the experimental beverages. This will allow us to assess the change from the postabsorptive to the postprandial period


Secondary Outcome Measures :
  1. Phosphorylation of muscle anabolic signaling [ Time Frame: Baseline and at 2 and 5 hours after protein ingestion ]
    Phosphorylation of anabolic signaling pathways will be assessed in the fasted state and at 2 and 5 hr after the ingestion of the whole egg and egg whites

  2. Exogenous rate of leucine appearance after ingestion of whole eggs and egg whites. [ Time Frame: 5 hour postprandial phase ]
    Dietary derived leucine availability will be measured during the 5 h postprandial phase to compare the dietary-derived leucine availability after whole egg and egg white ingestion.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male
  • Aged 18-35 years
  • Healthy, active (self-reported to exercise 2 - 4 times per week)
  • BMI > 18.5 and < 25 kg/m2

Exclusion Criteria:

  • Smoking
  • Known allergies to egg consumption
  • Vegans
  • Diagnosed GI tract diseases
  • Arthritic conditions
  • A history of neuromuscular problems
  • Diagnosed cognitive impairments
  • Recent (1 year) participation in amino acid tracer studies
  • Predisposition to hypertrophic scarring or keloid formation
  • Individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
  • High blood pressure (Systolic > 140 mm HG; Diastolic > 90 mm HG)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03117127


Locations
Layout table for location information
United States, Illinois
Freer Hall
Urbana, Illinois, United States, 61801
Sponsors and Collaborators
University of Illinois at Urbana-Champaign
Investigators
Layout table for investigator information
Principal Investigator: Nicholas A Burd, Ph.D. Assistant Professor

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Nicholas Burd, Assistant Professor, University of Illinois at Urbana-Champaign
ClinicalTrials.gov Identifier: NCT03117127     History of Changes
Other Study ID Numbers: 15693
First Posted: April 17, 2017    Key Record Dates
Last Update Posted: May 1, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertrophy
Pathological Conditions, Anatomical